Tzield (Teplizumab)

Teplizumab is a medicine that can delay type 1 diabetes in people at an early stage of it, and slow its progress in children who were just diagnosed. It is given as a drip into a vein (an infusion) once a day for 12 or 14 days. It works by calming the immune cells that attack the cells in the pancreas that make insulin.

Brand names:Tzield
Medication

What people taking Tzield (Teplizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Tzield (Teplizumab) for Type 1 Diabetes?

NameHow it went

About Tzield (Teplizumab)

What It's For

Tzield (teplizumab) is a prescription medicine for type 1 diabetes at an early stage, given as an infusion into a vein. Type 1 diabetes is an autoimmune disease: the immune system gradually destroys the beta cells in the pancreas that make insulin. That damage begins long before symptoms appear, and blood tests can find islet autoantibodies, immune proteins aimed at the pancreas, years before blood sugar rises enough for a diagnosis. Tzield has two approved uses in the US. The first is for people aged 1 year and older with Stage 2 type 1 diabetes. Stage 2 means a person has at least two of these autoantibodies and their blood sugar is already abnormal on testing, but not high enough to count as diagnosed diabetes. In this group, Tzield is used to delay Stage 3, the point at which type 1 diabetes is diagnosed clinically and insulin treatment is usually needed. The second use is for children and teens aged 8 to 17 who were diagnosed with Stage 3 type 1 diabetes within the past 8 weeks. Here the aim is to slow the loss of the insulin their own pancreas still makes. This use has accelerated approval from the FDA, meaning the decision rested on a lab marker of insulin production, and further studies are required to confirm a clinical benefit. Tzield is not a treatment for type 2 diabetes or other forms of high blood sugar that are not autoimmune. Evidence for its use in people 45 and older with Stage 2 disease is limited.

How It Works

Teplizumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is CD3, a molecule on the surface of T cells, the white blood cells that drive the immune attack on insulin-producing cells. By binding to CD3, teplizumab appears to quiet or wear out some of the T cells aimed at the pancreas, and it increases the share of regulatory T cells, which help keep immune responses in check. The exact mechanism is not fully understood. A short course does not permanently reset the immune system. It seems to slow the attack for a period, which can preserve the body's own insulin production for longer. Teplizumab does not replace insulin or lower blood sugar directly.

Dosage & Administration

Tzield is given only in a clinic or infusion center, as a drip into a vein (intravenous infusion) once a day on consecutive days. Each infusion takes at least 30 minutes, or at least 2 hours in children younger than 8. The dose is calculated from body size (height and weight) and starts low on the first days before stepping up. For Stage 2 type 1 diabetes, treatment is a single course of 14 daily infusions. For recently diagnosed Stage 3 type 1 diabetes in children and teens, it is two courses of 12 daily infusions. The first course should start within 8 weeks of diagnosis, and the second is given about 6 months later (no later than 12 months). Before treatment, blood tests check blood counts, liver function and whether there is an active Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection. Before each of the first 5 infusions, people receive a fever and pain reliever (acetaminophen or an anti-inflammatory such as ibuprofen) and an antihistamine, sometimes with an anti-nausea medicine, to reduce reactions. Blood counts are checked every 2 to 3 days during the course, and liver tests are monitored. If an infusion is missed, the remaining doses continue on consecutive days until the course is complete; two doses are never given on the same day.

Side Effects

The most common effect is a drop in lymphocytes, a type of white blood cell. It shows up on blood tests rather than as symptoms, happens in most people during treatment and usually recovers within about two weeks after the course ends, although it can last longer in adults. Rash is also common. Headache, nausea, vomiting and diarrhea can occur, and liver test results may rise. Some people develop cytokine release syndrome, a reaction caused by chemical signals released from activated immune cells. It brings fever, nausea, vomiting, tiredness, headache, and muscle or joint aches, and it mostly happens in the first five days of treatment, which is why premedication is given then. Tell the care team promptly about these symptoms; a severe reaction can mean pausing treatment for a day or two or stopping it. Because Tzield temporarily weakens part of the immune system, infections can become more serious. A rare but serious risk is reactivation of a virus already in the body, especially EBV or CMV, which can be life-threatening. Contact the care team right away for fever, feeling unwell, swollen glands or other signs of infection during treatment or for at least two months after the last infusion. Serious allergic reactions are also possible; swelling of the face, lips or throat, wheezing or trouble breathing needs immediate medical attention.

Interactions & Warnings

Tzield is not used in people whose immune system is already weakened (immunocompromised) or who have an active viral infection such as EBV or CMV. People with Down syndrome may be at higher risk of serious viral reactivation, and serious cases have also occurred in adults with larger body size or conditions such as heart disease or adrenal insufficiency. Treatment is also not recommended during an active serious or chronic infection, or when blood counts are very low or liver tests are abnormal beforehand. Vaccines need planning, because Tzield can weaken the body's response to them and live vaccines have not been studied with it. Age-appropriate vaccines are given first: live vaccines at least 8 weeks before starting, and inactivated or mRNA vaccines at least 2 weeks before. Afterward, inactivated and mRNA vaccines are avoided until 6 weeks after a course, and live vaccines until 52 weeks after the final course. Check with the care team before any vaccine, including between courses. Tzield should be avoided during pregnancy and for at least 30 days before a planned pregnancy, because antibodies like it can cross the placenta and may suppress a baby's developing immune system. Tell the care team about a known or possible pregnancy. A baby exposed before birth may need a specific plan before receiving live vaccines.

What to Expect

Treatment means two weeks or more of daily clinic visits, which takes planning around school or work. Most side effects, including the drop in white blood cells, cluster around the course itself and settle within weeks, while watching for infection continues for at least two months afterward. Tzield delays type 1 diabetes rather than preventing it. In the trial that led to its approval, 76 relatives of people with type 1 diabetes, aged 8 to 49 and at Stage 2, received a single 14-day course or a placebo. The median time until diagnosis was about 4 years with teplizumab versus about 2 years with placebo, and during follow-up 43% of treated participants were diagnosed compared with 72% on placebo. Responses varied, and the trial was small. Those extra years can mean a longer stretch without daily insulin and more time to prepare. In children and teens recently diagnosed with Stage 3, two courses preserved more of their own insulin production after about a year and a half than placebo did, measured by C-peptide, a substance the pancreas releases along with insulin. However, they did not need less insulin, and their HbA1c (average blood sugar over about 3 months), time in the target glucose range and low blood sugar episodes were not significantly different. Insulin treatment and routine diabetes care continue as before.

Questions to Ask Your Doctor

  1. 1.Do the test results confirm Stage 2 type 1 diabetes (or a recent Stage 3 diagnosis), and how much delay could treatment realistically give?
  2. 2.What would the daily infusions involve in time, travel and missed school or work?
  3. 3.Which vaccines need to be given before treatment, and how should we time them?
  4. 4.What signs of infection or viral reactivation should we watch for afterward, and whom do we call?
  5. 5.How will blood sugar be monitored after treatment, and what happens if diabetes develops anyway?

Last reviewed • Oct 2026

Educational content, not medical advice.